Treatments for blood sugar levels and muscle tissue optimization using extracorporeal acoustic shock waves
Abstract
A method of treating red blood cells of a human patient has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting a vascular system containing red blood cells and surrounding muscle tissue peripherally through an extremity of a patient to the acoustic shock waves by stimulating the extremity wherein the extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. The methods also treat muscle tissue of aging patients, from muscle regeneration or athletes for legal performance enhancement without drugs.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . The method of preventive shock wave therapy comprises the steps of:
identifying a diabetic at risk patient, the patient having an at risk baseline blood sugar level; and subjecting the at risk extremity to shock waves to lower said baseline sugar level.
2 . The method of preventive shock wave therapy of claim 1 wherein the step of identifying an at risk patient includes one or more indications of risk based on family history, genetic disposition, physical condition, or blood or extremity analysis.
3 . The method of preventive shock wave therapy of claim 1 further comprises the step of testing the at risk extremity to establish measured the baseline condition pre shock wave therapy.
4 . The method of preventive shock wave therapy of claim 1 further comprises the step of post shockwave therapy testing the blood sugar level for comparison to the baseline condition.
5 . The method of treating red blood cells of a human patient of claim 1 wherein repeating the method periodically a plurality of times over a period of weeks to lower said baseline level of blood sugar.
6 . A method of treating skeletal muscle tissue of an aging human patient comprises the steps of:
activating an acoustic shock wave generator or source to emit acoustic shock waves; and subjecting surrounding muscle tissue peripherally to the acoustic shock waves by stimulating the muscle tissue wherein the muscle tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.
7 . The method of treating an aging human patient of claim 6 wherein the emitted shock waves are divergent or near planar.
8 . The method of treating an aging human patient of claim 6 wherein the emitted shock waves are convergent having a geometric focal volume or point at a distance of at least X from the generator or source, the method further comprising positioning the extremity at a distance less than the distance X from the source.
9 . The method of treating an aging human patient of claim 6 wherein the patient is exhibiting one or more impairments such as: age related skeletal muscle atrophy and sarcopenia resulting in the loss of muscle capacity and mass, progressive motor neuron degeneration, increases in fat mass, decreases in lean muscle, bone mass, and cellular environmental aberrances are commonly seen alterations of aging muscle, impairments in metabolic rate, aerobic capacity, strength and balance, functional capacity, along with emotional and cognitive distress.
10 . The method of treating an aging human patient of claim 6 wherein the emitted shock waves are of a low intensity ranging from 0.10-0.12 mJ/mm 2 .
11 . A method of treating skeletal muscle tissue of a human patient to optimize athletic performance and muscle resilience comprises the steps of:
activating an acoustic shock wave generator or source to emit acoustic shock waves; and subjecting surrounding muscle tissue peripherally to the acoustic shock waves by stimulating the muscle tissue wherein the muscle tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.
12 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the emitted shock waves are divergent or near planar.
13 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the emitted shock waves are convergent having a geometric focal volume or point at a distance of at least X from the generator or source, the method further comprising positioning the extremity at a distance less than the distance X from the source.
14 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the patient is exhibiting one or more impairments such as: age related skeletal muscle atrophy and sarcopenia resulting in the loss of muscle capacity and mass, progressive motor neuron degeneration, increases in fat mass, decreases in lean muscle, bone mass, and cellular environmental aberrances are commonly seen alterations of aging muscle, impairments in metabolic rate, aerobic capacity, strength and balance, functional capacity, along with emotional and cognitive distress.
15 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the emitted shock waves are of a low intensity ranging from 0.10-0.14 mJ/mm 2 .
16 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the emitted shock waves cause a quick removal of lactic acid from the cells of the muscle tissue allowing quicker muscle recovery.
17 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the treatment causes rapid recovery from muscle cramping.
18 . The method of treating a human patient to optimize athletic performance and muscle resilience of claim 11 wherein the treatment is used for erectile dysfunction or penis performance enhancement.Join the waitlist — get patent alerts
Track US2022031563A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.